** Shares of Regulus Therapeutics RGLS.O more than double to $7.79 premarket
** Novartis offers to buy Regulus for $7/shr cash upfront and another $7/shr on hitting certain regulatory milestones for kidney disease drug farabursen
** Offer worth $800 mln on upfront price
** RGLS shares have already more than doubled this year through last close
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.